Established cardiac fibrosis (ECF) with symptomatic heart failure preserved ejection fraction represents an ever-increasing segment of the hypertensive population. The regression of ECF with attendant improvement in myocardial stiffness and symptomatic failure represents an unmet health care need. Is the regression of ECF in hypertensive heart disease feasible and will stiffness and symptomatic failure be improved? What is the cellular/molecular signaling involved in its regression? What incremental knowledge is needed to proceed effectively? These issues are addressed in this Review.
Hypertension affects more than 600 million people worldwide; it contributes importantly to increased risk of major cardiovascular events. An estimated 30% of the world's population will have hypertension within the next decade. When hypertensive persons first present to their primary care provider, many will already have established cardiac fibrosis (ECF) and heart failure with preserved ejection fraction now representing 50% of patients having symptomatic failure.
ECF is a "final common pathway to cardiac failure" and when established, it determines long-term outcomes and prognosis. [1] [2] [3] [4] Hence, the partial or complete regression of this interstitial fibrosis with intended improvements in ventricular function and patient prognosis represent an unmet worldwide health care need. [4] [5] [6] Herein, we review the regression of ECF in hypertensive heart disease. Is it feasible and will its regression be accompanied by improvements in myocardial stiffness? What is the cellular/molecular signaling involved in its regression? Finally, what missing gaps in our knowledge need to be answered to proceed effectively?
IS THE REGRESSION OF ECF FEASIBLE?
The myofibroblast secretome
The regression of ECF has been realized by recognizing the "living" nature of fibrous tissue, or secretome imparted by a persistent, apoptosis-resistant population of fibroblast-like cells expressing alpha-smooth muscle actin microfilaments, termed "myofibroblasts (myoFb)", the "cellular element common to all fibrotic organs" irrespective of etiologic origins. 5, 6 Fibrosis is based on a myoFb fibrogenic signaling pathway involving upregulated collagen synthesis and downregulated degradation. "Redox-sensitive myoFb" are responsible for the ongoing turnover of collagen at sites of fibrosis, where they are "persistent" and "resistant" to programmed cell death conferred by transcription factor NFκB and the prosurvival genes it regulates. These persistent myoFb are "metabolically active" (reviewed in 6) having secretory activity that regulates their phenotype and collagen turnover in an autocrine manner ( Figure 1 ). This secretome includes a "fibrogenic ACE/AngII/AT 1 R axis", with "AngII/AT 1 R" the most proximal upstream autocrine signal regulating type I and III fibrillar collagen synthesis via a downstream TGF-β 1 / Smad pathway.
This fibrogenic axis is opposed by a "counter-regulatory ACE2/Ang1-7/MasR axis". The "Ang1-7/MasR" regulates the equilibrium between endogenous tissue inhibitors (TIMP-1/-2) and matrix metalloproteinases (MMP-2/-9) and is fibrolytic in nature (Figure 1 ). ACE2 increases MMP-2 activity, whereas AngII inhibits this effect through AT 1 R and ERK1/2 signaling.
Experimental findings
The feasibility of regressing ECF has been demonstrated in both adult and senescent rats with genetic hypertension (spontaneously hypertensive rats [SHR] ). Treatment with lisinopril regressed cardiac fibrosis in adult SHR and in 78-week-old senescent SHR and improved ventricular stiffness. [7] [8] [9] [10] Losartan treatment in SHR regressed established fibrosis and improved myocardial stiffness associated with reduced TIMP-1 and increased collagenase activity. 9, 11 
Clinical findings
In a preliminary clinical study, 12 6 months treatment with lisinopril was compared to hydrochlorothiazide in 35 hypertensive patients with left ventricular hypertrophy. Lisinopril led to the partial regression of biopsy-proven ECF and improved echocardiographic evidence of abnormal ventricular stiffness. This contrasted to equipotent doses of the thiazide diuretic which provided a comparable reduction in blood pressure, but no regression in fibrosis or left ventricular hypertrophy. In hypertensive patients, having hypertensive heart disease and left ventricular hypertrophy, a partial regression of biopsy-proven established fibrosis was found with 12 months losartan treatment, 13 which was not seen with amlodipine, a Ca 2+ channel blocker. 14 In a randomized trial in 219 hypertensive patients with established fibrosis, 36 weeks treatment with losartan was compared to atenolol, a β blocker, with or without thiazide diuretic. Noninvasive markers of cardiac collagen content were reduced by losartan but not by atenolol. 15 Both lisinopril and losartan may have additional salutary responses in patients having resistant hypertension by reducing inappropriate plasma aldosterone concentrations 16 with its profibrotic properties.
Summary
Thus, the regression of ECF and improvement in myocardial stiffness, using either an ACEI or AT 1 Ra, has been demonstrated in hypertensive rodents of diverse etiologic origins and hypertensive humans together with an improvement in myocardial stiffness. Collectively, these findings serve as "proof of concept" that the reversal of ECF is indeed feasible with these agents. In patients having heart failure with reduced ejection fraction, which includes those with ischemic cardiomyopathy having one or more transmural infarct scars, 17 the regression of such scar tissue is not warranted and indeed could prove seriously detrimental in this now-repaired hollow muscular organ. Furthermore, dosing and duration of treatment with these agents may be relevant to the partial or complete regression of ECF in patients having nonischemic cardiomyopathy.
CELLULAR/MOLECULAR SIGNALING INVOLVED IN THE REGRESSION OF ECF
The fibrogenic ACE/AngII/AT 1 R axis of the myoFb reninangiotensin system (Figure 1 ) plays a central role in regulating growth and activity. Signaling mechanisms responsible for fibrosis relate to this axis. ACEI and AT 1 Ra regress cardiac fibrosis in both hypertensive rodents and man.
The "regression of ECF" accompanies treatment with either an ACEI or AT 1 Ra in both adult and senescent rats with genetic hypertension (SHR) and in hypertensive patients with endomyocardial biopsy-proven cardiac fibrosis, where MMP activity was increased and respective organ function improved. 7-9,12-14 The myoFb renin-angiotensin system has expanded with a novel axis of ACE2, Ang1-7, and the G protein-coupled receptor, Mas. 18 This ACE2/Ang1-7/ MasR axis counter-regulates the deleterious fibrogenic ACE/ AngII/AT 1 axis and therefore could regress cardiac fibrosis (Figure 1) . ACEI inhibitors and AT 1 Ra upregulate the ACE2/ Ang1-7/MasR axis in the hypertensive heart (reviewed in 18). Inhibition of ACE2/Ang1-7/MasR axis exacerbates 19 while Ang1-7 overexpression prevents fibrosis. [20] [21] [22] Signaling mechanisms involved in the regression of fibrosis have the potential to be applied to the development of ACE2 activators and MasR agonists, 23 as both antihypertensive and antifibrotic agents. Prevention of fibrosis has been reported in SHR for ACE2 activators [24] [25] [26] [27] [28] and nonpeptide synthetic Mas receptor agonists. 29 However, no information exists as to the regression of ECF and which is independent of inflammatory cells involved in its appearance.
FUTURE DIRECTIONS
Molecular mechanisms involved in the rescue of ECF and the role of the myoFb secretome with its fibrogenic and fibrolytic axes needs further investigation. Whether the fibrolytic axis stimulates the clearance of myoFb through inhibition of redox-sensitive NFκB (and the prosurvival genes it regulates) while any remaining myoFb may have a quiescent phenotype (remaining after treatment withdrawal) is of particular interest.
These fundamental signaling mechanisms could be applied to the development of newer ACE2 activators and MasR agonists as both antihypertensive and antifibrotic agents. Increased mechanistic knowledge applicable to the development of newer pharmacologic agents as antifibrotic agents and based on enhancing the formation of Ang1-7. 29 Heterogeneity in the regression of ECF between these ACEI and AT 1 Ra would suggest important differences and directions for newer agents. Examples where discovery and incremental knowledge is needed are given. Both of these agents induce ACE2, but will ACEI exhaust ACE-based production of AngII substrate as a rate-limiting step in Ang1-7 formation? Alternate sources of AngII generation are available, including chymase-based production of AngII from Ang1-12 to mitigate against this limitation, and a positive feedback loop exists with ACE2 increasing Ang1-7 when ACEI have reduced AngII substrate. ACEI is also a kininase II inhibitor with increased bradykinin and B 2 R-mediated release of NO (from eNOS and iNOS) and prostaglandins serving as antioxidants involved in the induction of MMP-2/-9 not seen with AT 1 Ra. A crosstalk exists between MasR, B 2 R, and AT 2 R with heterodimerization between receptors promoting Ang1-7 effects and enhanced production of NO and prostaglandins and role of bradykinin not seen with an AT 1 Ra. Will ACEI and AT 1 Ra attenuate NADPH oxidase activity and phosphorylation of ERK1/2, STAT3, Akt, and Gsk3β with deactivation of TIMP-1/-2 be comparable antioxidants?
The intended impact of such research will ultimately be in advancing the practice of medicine through the rapid transfer of incremental knowledge aimed at optimizing the management of hypertensive patients having ECF and heart failure preserved ejection fraction and who might be identified by serologic markers of fibrosis or magnetic resonance imaging. 2, 3, 13 This advancement would occur through the understanding of regulatory events and molecular signaling governing myoFb secretome in response to these currently available antihypertensive agents with off-label antifibrotic effects and in the transfer of these findings to advancing newer compounds as having antifibrotic properties in the regression of ECF.
SUMMARY AND CONCLUSIONS
Fibrosis is the final common denominator to organ failure and this holds true for the heart as it contributes to the progressive nature of hypertension. Based on substantial preliminary data, gathered worldwide in hypertensive rodents and man with ECF, its regression can be attained with lisinopril or losartan treatment. The novelty of this approach begins with its simplicity using proven agents with off-target antifibrotic effects. Its scope expands regulatory events involving molecular signaling mechanisms which govern myoFb secretome in response to these agents in promoting such regression. It further includes the rapid transfer of scientific discoveries and incremental knowledge into transformative potential. Responses to Lis and Los in promoting the regression of ECF with improved myocardial stiffness will be related to the myoFb fibrolytic axis with an upregulation of the counter-regulatory ACE2/Ang1-7/MasR axis will deactivate the fibrogenic ACE/AngII/AT 1 R axis and promote the clearance of myoFb phenotype.
Heretofore, the regression of ECF with cross-linked fibrillar collagen has been considered beyond reach. This dogma no longer prevails. We would opine the secretory activity of activated myoFb, residing at sites of fibrosis, can be harnessed with Lis and Los to promote regression of fibrosis and recovery of organ function. Such activity could be applied to newer ACE2-related antihypertensive compounds as antifibrotic agents.
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